Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes.
AffiliationDepartment of Medicine, Cork University Hospital, Wilton, Cork, Ireland., email@example.com
Diabetes Mellitus, Type 1/metabolism/*physiopathology
Drug Administration Schedule
Hemoglobin A, Glycosylated/analysis
Hypoglycemic Agents/administration & dosage
Insulin/administration & dosage
MetadataShow full item record
CitationDiabet Med. 2006 May;23(5):557-64.
JournalDiabetic medicine : a journal of the British Diabetic Association
AbstractAIMS: To assess the effects of weight gain on metabolic control, plasma lipids and blood pressure in patients with Type 1 diabetes. METHODS: Patients in the EURODIAB Prospective Complications Study (n = 3250) were examined at baseline and 1800 (55%) were re-examined a mean of 7.3 years later. Patients had Type 1 diabetes, defined as a diagnosis made before age 36 years and with a need for continuous insulin therapy within a year of diagnosis. Patients were aged 15-60 years at baseline and were stratified for age, sex and duration of diabetes. RESULTS: The change in HbA(1c) from baseline to follow-up examination was significantly more favourable in those who gained 5 kg or more during follow-up ('marked weight gain') than in patients who gained less or no weight or lost weight ('less or no weight gain'). In those with marked weight gain, there was a significantly greater rise in plasma triglycerides and total cholesterol and significantly less favourable changes in low-density lipoprotein and high-density lipoprotein cholesterol compared with those with less or no weight gain, with or without adjustment for HbA(1c). Systolic and diastolic blood pressure also rose significantly more in the group with marked weight gain. CONCLUSION: Weight gain in patients with Type 1 diabetes has adverse effects on plasma lipids and blood pressure, despite a small improvement in glycaemic control.
- Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study.
- Authors: Citro G, Lorusso B, Rossi A, Romaniello M, Gentilella R, Cremasco F
- Issue date: 2009 Sep
- Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
- Authors: Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, Stehouwer CD
- Issue date: 2003 Apr
- Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
- Authors: Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD
- Issue date: 2006 May
- Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
- Authors: Berhanu P, Perez A, Yu S
- Issue date: 2007 Jul
- The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
- Authors: Rajagopalan R, Xu Y, Abbadessa M, Quartet Study Group.
- Issue date: 2006 Jun